We also found that CRC patients with CXCR3+ tumors showed significantly shorter survival rates than those without CXCR3, and that CRC patients with tumors double-positive for both CXCR3 and CXCR4 had a significantly poorer prognosis than those with tumors positive only for CXCR4 or those that were double-negative [22,58]. The gene discussed is CXCR3; the disease is colorectal carcinoma.